The world's leading journal on infectious diseases. Clinical ID, public health, microbiology, and everything in-between. Official publication of @IDSAinfo
Joined February 2022
- Tweets 3,653
- Following 11
- Followers 22,418
- Likes 395
2,331 Photos and videos
Markers of immune function and survival among cancer patients with HIV in the United States: a population-based registry linkage study
β
Just Accepted
βοΈ @camcanepi
bit.ly/4dLWZQa
1
1
183
Further unraveling the association between HIV, immune suppression, and cancer survival
β
Just Accepted
π bit.ly/4vGiXKk
1
6
585
Near-point-of-care diagnosis of tuberculosis with LyocartE MTB Assay: a multicentre diagnostic accuracy study
β
Just Accepted
bit.ly/4aMNBto
3
5
695
Persistent evidence practice gap in antibiotic use for community acquired pneumonia
β
Just Accepted
π bit.ly/4a068Cd
2
6
625
Efficacy and acceptability of liraglutide for obesity in people with HIV: results of an open-label clinical trial in South Africa
β
Just Accepted
bit.ly/4vPAgJa
1
1
614
Donβt Drop the B: Risk of Hepatitis B Virus Infection and Reactivation in the Era of Tenofovir-Sparing Regimens for Treatment and Prevention of HIV
β
Just Accepted
βοΈ @HowardTLeeMD
π bit.ly/3RXJXXg
3
8
724
More Attention on Infection-Associate Chronic Conditions Requires Restoring Support for Long COVID
β
Just Accepted
π bit.ly/4vIpkwU
1
4
443
Early Discontinuation of Empiric Antibiotics in Pediatric Haploidentical Hematopoietic Cell Transplant Recipients with Febrile Neutropenia
β
Just Accepted
βοΈ @StJudeResearch
bit.ly/4umVnBd
2
2
501
What if Goldilocks Had a Choice? Rethinking the Optimal Duration of Empiric Antibiotics in Pediatric Hematopoietic Cell Transplant Recipients with Persistent Fever and Neutropenia
β
Just Accepted
π bit.ly/4v3mZww
1
406
Can Influenza Virus Cause Bacteremia, Sepsis, and Septic Shock?
β
Just Accepted
#IDTwitter
π bit.ly/4usrnEj
1
5
10
713
The latest CID supplement issue highlights the clinical and research framework needed to combat antimicrobial resistance and accelerate progress in antibiotic development.
βͺοΈ bit.ly/4xgx8r2
2
669
Use of dolutegravir to treat people living with HTLV-1-associated myelopathy (HAM)
β
Just Accepted
π bit.ly/4erBxjx
1
3
765
Population sensitive linezolid monitoring during global implementation of BPaL based regimens
β
Just Accepted
π bit.ly/4dRoBTY
5
8
1,184
Prevalence and Outcomes of Bacterial Co-detections by Blood Culture Among Children and Adults Hospitalized With Laboratory-confirmed Influenza, Influenza Hospitalization Surveillance Network, 2022β2024
β
Just Accepted
π bit.ly/4xbASKr
2
7
688
Virological Response Versus Clinical Benefit in HAM/TSP
β
Just Accepted
#IDTwitter
π bit.ly/4uaNMpd
1
3
672
The role of dolutegravir on therapy of HTLV-1 infection
β
Just Accepted
#IDTwitter
π bit.ly/49GtAEx
1
5
957
Safety of short-course weekly rifapentine and isoniazid (3HP) for TB preventive treatment at conception and during first trimester in women living with HIV: a secondary analysis of WHIP3TB trial
β
Just Accepted
βοΈ @Auruminstitute
π bit.ly/4fkdtjz
3
4
682
A randomized clinical trial to compare moxiFloxAcin veRsus aziTHromycin for the trEatment of MycoplaSma geniTalium: the FARTHEST Study
β
Just Accepted
π bit.ly/4x8gj1w
3
5
659
Three Months of Weekly Rifapentine and Isoniazid Versus Four Months of Daily Rifampicin for Tuberculosis Infection: A Randomized Controlled Trial
β
Just Accepted
π bit.ly/4o11Yje
4
7
851